Contineum’s JNJ-5120/PIPE-307 Misses Phase 2 MDD Endpoint

Contineum Therapeutics announced that its Phase 2 MOONLIGHT-1 clinical trial evaluating JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint. The randomized, double-blind, multicenter, placebo-controlled proof-of-concept study evaluated the small molecule as a monotherapy in adults with major depressive disorder (MDD).

The primary endpoint measured change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared to placebo. The trial failed to demonstrate statistical significance on this measure, and neither company disclosed numerical MADRS scores, treatment effect size, confidence intervals, or p-values.

M1 Receptor Targeting in Major Depressive Disorder

JNJ-5120/PIPE-307 is a selective muscarinic M1 receptor antagonist. The therapeutic rationale relies on selective M1 receptor modulation to influence cholinergic signaling pathways and neural circuits that govern mood and cognitive function.

MDD remains a major unmet medical need in psychiatry. Standard oral antidepressants typically require several weeks to produce meaningful clinical benefit, and a substantial proportion of patients do not achieve adequate response to first-line agents. A therapeutic candidate capable of driving rapid symptom reduction such as the Day 5 onset targeted in MOONLIGHT-1 would address a key gap in acute depression management.

Contineum out-licensed global development and commercialization rights for PIPE-307 to Johnson & Johnson (J&J) in 2023. The deal included a $50 million upfront payment, a $25 million equity investment, and up to $1 billion in potential milestone payments, with J&J assuming sole responsibility for ongoing global clinical development.

MOONLIGHT-1 Readout and Pipeline Implications

While JNJ-5120/PIPE-307 was reported to be well-tolerated with no new safety signals identified, the primary efficacy miss represents a significant clinical obstacle. J&J is analyzing prespecified exploratory endpoints to evaluate whether the broader dataset contains evidence of secondary activity to justify continued development.

This result follows a prior Phase 2 setback for PIPE-307 in relapsing-remitting multiple sclerosis (RRMS), compounding clinical uncertainty surrounding the compound’s overall utility.

Next Steps for J&J and Contineum

J&J will assess the overall clinical relevance of the MOONLIGHT-1 findings before determining whether to advance, modify, or discontinue the program. No official timeline for this decision has been announced.

For Contineum, the outcome elevates the strategic importance of its wholly owned internal clinical pipeline. Company valuation will depend heavily on candidates like PIPE-791, an oral LPA1 receptor antagonist currently in clinical development for idiopathic pulmonary fibrosis (IPF) and chronic pain.

The next catalyst for PIPE-307 hinges on whether J&J discloses secondary or exploratory findings from the trial. Until those data are released, the drug’s efficacy in MDD remains unproven and the future of the asset remains uncertain

Reference

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder, Contineum Therapeutics, 14 September 2026

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder (Moonlight-1), ClinicalTrials.gov ID NCT06785012